VJHemOnc Podcast cover image

VJHemOnc Podcast

Latest episodes

undefined
Apr 25, 2025 • 35min

Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment

In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). They cover key topics such as diagnostic advancements, frontline treatment strategies based on IGHV mutational status, the role of double oral combinations, the importance of measurable residual disease (MRD)-guided treatment, and the debate between time-limited and continuous regimens. The post Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment appeared first on VJHemOnc.
undefined
Apr 17, 2025 • 23min

Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more

In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation. Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, provide insights into current treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll hear about cytomegalovirus (CMV) management from Per Ljungman, MD, PhD, Karolinska Institute, Stockholm, Sweden, and human herpesvirus 6 (HHV-6) diagnosis from Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, and Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy. Finally, Manuela Spadea, MD, University of Turin, Turin, Italy, comments on ushering in the era of the hematologist-AI alliance, and Adrián Mosquera-Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, highlights the potential for harnessing machine learning to predict post-SCT outcomes in patients with myelofibrosis (MF). The post Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more appeared first on VJHemOnc.
undefined
Apr 14, 2025 • 46min

Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more!

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). They focus on the sequencing of CAR T-cells and bispecific antibodies in diffuse large B-cell lymphoma (DLBCL), the use of BTK inhibitors (BTKis) in mantle cell lymphoma (MCL), and advances in the treatment of follicular lymphoma. The post Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more! appeared first on VJHemOnc.
undefined
Mar 31, 2025 • 18min

Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms

CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cell product. This episode also covers studies of trispecific CAR T-cells targeting CD19, CD20, and CD22. Stay tuned to learn more about these promising approaches from experts Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Armin Ghobadi, MD, Washington University School of Medicine, St. Louis, MO, Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain. The post Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms appeared first on VJHemOnc.
undefined
Mar 28, 2025 • 23min

Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Selina Luger, MD, FRCPC, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, Harry Erba, MD, PhD, Duke University, Durham, NC, Fabio Guolo, MD, University of Genoa, Genoa, Italy, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL. The experts discuss key trials in this space, including venetoclax combined with intensive induction chemotherapy, a Phase II study comparing midostaurin with gilteritinib in FLT3-mutated AML (NCT03836209), and the combination of ziftomenib with intensive chemotherapy. They also examine the role of CPX-351 in induction therapy and its potential combination with gemtuzumab ozogamicin. The post Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! appeared first on VJHemOnc.
undefined
Mar 24, 2025 • 17min

Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients. In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, and David Lewis, MD, Plymouth University, Plymouth, UK. The experts cover a variety of topics, exploring the role of BTK inhibitors in R/R MCL, promising combinations being explored, and strategies to overcome resistance. The post Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance appeared first on VJHemOnc.
undefined
Mar 14, 2025 • 28min

Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!

In this enlightening discussion, Joseph Mikhael, a myeloma expert from TGen and the International Myeloma Foundation, tackles the pressing issues in myeloma treatment. He highlights breakthroughs in managing smoldering myeloma and the unique challenges faced by frail and elderly patients. The conversation also dives into innovative therapies for triple-class refractory disease, and the critical examination of racial disparities in myeloma care. Mikhael’s insights showcase the need for improved access and personalized treatment approaches.
undefined
Feb 27, 2025 • 19min

CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes

Discover groundbreaking updates on CAR T-cell therapy for acute lymphoblastic leukemia. Experts discuss the pivotal CART19-BE-02 trial results and the FDA approval of obecabtagene autoleucel for relapsed B-ALL. Insights into the safety and efficacy of brexucabtagene autoleucel for older patients highlight promising outcomes. Innovative trials, including a phase two study of WU-CAR and tri-specific CAR T-cells, showcase strong safety profiles and exciting potential for future treatments in hematological malignancies.
undefined
Feb 21, 2025 • 13min

Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!

In this insightful discussion, Vaishali Sanchorawala, a leading expert in amyloidosis from Boston University, and Ashutosh Wechalekar, a prominent hematologist from University College London, delve into the cutting-edge findings presented at the recent ASH meeting. They highlight breakthrough results from the ANDROMEDA trial, emphasizing the effectiveness of daratumumab VCD for AL amyloidosis treatment. The duo also explores advancements in risk stratification and the promising role of measurable residual disease and CAR T-cell therapy in enhancing patient care.
undefined
Feb 14, 2025 • 18min

Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia

Dr. Rabi Hanna from Cleveland Clinic shares insights on innovative treatments for severe sickle cell disease. He presents updated results from the RUBY trial, highlighting the potential of reni-cel as a groundbreaking gene therapy. The conversation also touches on the promising outcomes of the HIBISCUS trial for Etavopivat, showing significant improvements in patient quality of life. Furthermore, advancements in thalassemia treatments are discussed, focusing on reduced transfusion needs from the ENERGIZE-T study.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner